Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial
Authors' conclusion
Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.
Study context
- Population
- Patients with acute MI and TIMI flow grade ≤ 2 (angiographic microvascular obstruction (MVO)) after primary percutaneous coronary intervention (PCI)
- Participants
- 120 patients
- Comparison
- Glycoprotein (GP) IIb/IIIa inhibitor vs no GP IIb/IIIa inhibitor
- GP IIb/IIIa inhibitorn = 62
- Primary endpoint
- Infarct size (% of left ventricular (LV) mass) by cardiac magnetic resonance (CMR)
Methodological detailsinvestigator-initiated, international, multicentre
- Investigator-initiated
- International
- Multicentre
Primary result
As reported in the abstract
Infarct size by CMR
P = 0.386
Secondary outcomes
Patients with CMR-derived MVO
P = 0.017
All-cause mortality · 30 days
P = 0.703
Extent of MVO
P = 0.025
Safety
Non-life-threatening bleeding · 30 days
P = 0.016
Original publication
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial. Eur Heart J. Published 1 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →